

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement appears for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities of the Company.

RepublicHealthcare

Republic Healthcare Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 8357)

APPOINTMENT OF DEPUTY CHIEF EXECUTIVE OFFICER AND RESIGNATION OF CHIEF EXECUTIVE OFFICER

The board (the “**Board**”) of directors (the “**Directors**”) of Republic Healthcare Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) announces that with effect from 16 November 2020:

RESIGNATION OF CHIEF EXECUTIVE OFFICER

Dr. Tan Kok Kuan (“**Dr. K. K. Tan**”) has resigned as the Chief Executive Officer of the Group as Dr. K. K. Tan desires to devote more time to his clinical practice. Dr. K. K. Tan has confirmed to the Board that he has no disagreement with the Board and that there are no other matters relating to his resignation that need to be brought to the attention of Directors, shareholders of the Company and the Stock Exchange.

APPOINTMENT OF DEPUTY CHIEF EXECUTIVE OFFICER

Dr. Ng Siew Boon (“**Dr. Ng**”) has been appointed as the Deputy Chief Executive Officer of the Group and is responsible for the operations, management and medical affairs of the Group.

Dr. Ng, aged 43, graduated from National University of Singapore in 2002 with a Bachelor of Science degree in microbiology and obtained his Master of Science degree in 2005 and Bachelor of Medicine and Bachelor of Surgery degree in 2009 from the University of Sydney in Australia.

Dr. Ng has over 10 years of experience in medical practice. During 2009, Dr. Ng worked in Australia as an intern doctor in the areas of respiratory medicine, vascular surgery, rehabilitation medicine and adult emergency medicine. Dr. Ng then returned to Singapore and since 2010, he worked in the areas of paediatrics emergency and microbiology as well as supervising hospital projects at various public hospitals in Singapore. Between 2015 to 2018, Dr. Ng joined Parkway Shenton network to continue his private medical practice. As Dr. Ng sees his special interests in paediatrics, chronic diseases

management and sexually transmitted diseases, he joined the Group in January 2018 and was promoted to the chief medical officer since January 2020 and is currently practicing at the Novena branch of the Group.

Dr. Ng has entered into a service agreement with the Company for the appointment as the deputy chief executive officer for a fixed term of one year and is entitled to a fee of SGD199,200 per annum, which has been determined by the Board upon the recommendation of its remuneration committee by reference to the qualifications, experience, duties and responsibilities within the Group of Dr. Ng and the prevailing market conditions.

As at the date of this announcement, save as disclosed in this announcement, Dr. Ng does not (i) hold any other position in the Company or other members of the Group; (ii) hold any directorships in the last three years in other listed companies; (iii) have other major appointments and professional qualifications; (iv) have any interests or short positions or is not deemed to have any interests or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); and (v) have any relationship with any Directors, senior management, substantial shareholders or controlling shareholders (as respectively defined in the Rules Governing the Listing of Securities on GEM of the Stock Exchange (the “**GEM Listing Rules**”)) of the Company.

Save as disclosed above, there is no other matter that needs to be brought to the attention of the shareholders of the Company nor other information relating to Dr. Ng that is required to be disclosed pursuant to Rule 17.50(2)(h) to (v) of the GEM Listing Rules.

The Board takes this opportunity to express its sincere gratitude to Dr. K. K. Tan for his contribution to the Group and extend its warmly welcome to Dr. Ng on his appointment as the Deputy Chief Executive Officer.

The Company is endeavouring to identify a suitable candidate to be appointed as the Chief Executive Officer and will make further announcement(s) as and when appropriate.

By order of the Board
Republic Healthcare Limited
Tan Cher Sen Alan
Chairman and Executive Director

Singapore, 16 November 2020

As at the date of this announcement, the executive Director is Dr. Tan Cher Sen Alan (Chairman) and the independent non-executive Directors are Mr. Low Wee Siong, Mr. Soh Sai Kiang and Mr. Kevin John Chia.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquires, confirm that to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the GEM website at www.hkgem.com for at least seven days from the day of its publication. This announcement will also be published on the Company’s website at republichealthcare.asia.